title: Testicular function after radioiodine therapy in patients with thyroid cancer.
abstract: Our aim was to assess testicular function in patients treated with high-dose radioiodine. Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels were determined in 52 men with thyroid carcinoma before and 6, 12, and 18 months after radioiodine therapy (3.7-5.5 GBq (131)I; mean, 4.25 GBq (131)I) (group 1) and were also determined before and 18 months after the last radioiodine therapy in 22 patients who received high cumulative activities (13-27.7 GBq; mean, 20.3 GBq (131)I) (group 2). FSH levels were increased 6 months after therapy in all patients of group 1, while a decline was observed after 12 months, with 37 of 52 (71%) subjects presenting normal values. FSH values returned to normal after 18 months in all patients. In group 2, 12 of 22 (54.5%) patients presented elevated FSH and 8 (66%) of these individuals had oligospermia. Six months after radioiodine, increased LH levels were observed in only 5 of 52 (9.6%) patients of group 1, which returned to normal after 12 months, and in 5 of 22 (22%) of group 2. All patients showed normal testosterone levels. We conclude that 131I therapy may cause impairment of testicular function. A generally transient increase in FSH is highly common but is usually reversed within 18 months. Oligospermia was common (one third) after high cumulative (131)I activities. Becausee we did not perform a spermiogram before therapy, we cannot state that high cumulative (131)I activities cause permanent infertility. We recommend the routine use of sperm banks in the cases of men who still wish to have children and who will undergo therapy with (131)I activities of 14 GBq or more or in the case of patients with pelvic metastases.
authors.affiliation: Department of Thyroid, Endocrinology Service, Santa Casa Belo Horizonte, Minas Gerais, Brazil. pedrorosario@globo.com.br
authors.forename: Pedro W S
authors.initials: PW
authors.lastname: Rosário
authors.forename: Alvaro L
authors.initials: AL
authors.lastname: Barroso
authors.forename: Leonardo L
authors.initials: LL
authors.lastname: Rezende
authors.forename: Eduardo L
authors.initials: EL
authors.lastname: Padrão
authors.forename: Michelle A R
authors.initials: MA
authors.lastname: Borges
authors.forename: Valéria C
authors.initials: VC
authors.lastname: Guimarães
authors.forename: Saulo
authors.initials: S
authors.lastname: Purisch
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013094:Spermatozoa / Q000378:metabolism; D013737:Testis / Q000502:physiology* / Q000528:radiation effects*; D013739:Testosterone / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone